 ImmunityBio Inc NASDAQ: IBRX has received FDA authorization to conduct a Phase 1 study to evaluate the m-ceNK platform combined with Anktiva N-803 in locally advancedmetastatic solid tumors. Cryopreserved m-ceNK cells combined with Anktiva will be tested in this QUILT 3.076 Phase 1 study designed to evaluate the safety in subjects. 